RT Journal Article
SR Electronic
T1 Genotypic and phenotypic analysis of 173 patients with extremely rare pathogenic mutations who applied for experimental antisense oligonucleotide treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.05.24310862
DO 10.1101/2024.08.05.24310862
A1 Crooke, Stanley T.
A1 Cole, Tracy
A1 Carroll, Jeffrey B.
A1 Gleeson, Joseph G.
A1 Mignon, Laurence
A1 Douville, Julie
A1 Chung, Wendy
A1 Bain, Jennifer
A1 Berry-Kravis, Elizabeth
A1 Leung, Nelson
A1 Demarest, Scott
A1 McCourt, Emily
A1 Watt, Andy
A1 Powers, Berit
A1 Tekendo-Ngongang, Cedrik
YR 2024
UL http://medrxiv.org/content/early/2024/08/06/2024.08.05.24310862.abstract
AB Recent advances in “omics” technologies allow for the identification of an increasing number of individuals with diseases caused by nano-rare mutations. These difficult-to-diagnose individuals are uniquely disadvantaged and pose significant challenges to healthcare systems and society. Despite having diseases caused by actionable single gene mutations, in many cases, there is no commercial path for treatments for such small patient populations. Since antisense oligonucleotide (ASO) technology has proven to be suited to address the needs of a portion of these patients, the n-Lorem Foundation is establishing an industrialized approach that couples detailed genotypic and phenotypic data to the immediate potential for ASO therapy. In this manuscript we have leveraged our experience in assessing the causality of nano-rare genetic variants and associated proximal molecular pathological events to attempt a correlation between detailed genetic data with patient specific phenotypic observations in 173 nano-rare individuals from diverse age groups evaluated for experimental ASO therapy. We found that the time required to achieve a molecular diagnosis varies from 1 month to 36 years, with the mean and median times from symptom onset to diagnosis estimated to be 4.32 years and 2 years, respectively. Amongst submitted cases there is a significant bias toward neurological diseases, with diverse genes and functional families involved and a marked preponderance of mutations in ion channel genes. The variability in phenotypic expression associated with nano-rare variants in genes such as GNAO1, H3F3A, GBE1, UBTF, or PACS1 clearly supports previous observations that phenotypes associated with same variants in the same gene can vary. We also observe that different, but functionally equivalent variants can result in both similar (e.g., TARDBP) and different phenotypes (e.g., GNAO1). Despite the relatively small size of the patient population investigated, this first compilation of its kind allows a variety of insights into the genotype and phenotype relationships in nano-rare conditions. Moreover, we show that our unique patient population presents a remarkable opportunity to apply “modern omics” approaches to begin to understand the various homeostatic, compensatory, and secondary effects of these genetic variants on the networks that result in expression of their unique phenotypes.To provide a more detailed description of the processes involved to provide a personalized antisense medicine, we have included nonclinical and clincal data on four exemplary patients who display disease in three different organs, the CNS, the eye and the kidney and are treated with ASOs of different designs. In contrast to traditional drug development, each patient presents unique genomic, ASO design, clinical treatment and management and evaluation challenges.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIND161670; IND162638; IND166588; IND159493Funding StatementThis study was funded by donations to n-Lorem.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from all patients involved prior to study start. All patients treated in this manuscript were treated under FDA approved INDs and after approval from each Institutional Review Board(s) (IRB). Ethics committee/IRB of Mayo Clinic Institutional Review Boards gave ethical approval in IRB Application # 22-005092 for this work Ethics committee/IRB of Children's Hospital Colorado gave ethical approval in IRB Application # 22-2313 for this work. Ethics committee/IRB of Columbia University Medical Center gave ethical approval in IRB Application # AAAU1165 for this work. Ethics committee/IRB of Rush University Medical Center gave ethical approval in IRB Application # irbm-006-002 for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors